Trial · NCT03363321
Results by group255
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 255
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) | Cohort 1: 300mg - 300mg Non-Inhibitor | All-causalities TEAE | 5 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) | Cohort 2: 300mg Loading + 150mg - 300mg Loading + 150mg Non-Inhibitor | All-causalities TEAE | 2 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) | Cohort 3: 450mg - 300mg Loading + 150mg Non-Inhibitor | All-causalities TEAE | 4 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) | Cohort 4: 300mg - 300mg Inhibitor | All-causalities TEAE | 2 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) | Cohort 5: De Novo 300mg Loading + 150mg Inhibitors | All-causalities TEAE | 1 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) | Cohort 1: 300mg - 300mg Non-Inhibitor | Treatment-related TEAE | 2 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) | Cohort 2: 300mg Loading + 150mg - 300mg Loading + 150mg Non-Inhibitor | Treatment-related TEAE | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) | Cohort 3: 450mg - 300mg Loading + 150mg Non-Inhibitor | Treatment-related TEAE | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) | Cohort 4: 300mg - 300mg Inhibitor | Treatment-related TEAE | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) | Cohort 5: De Novo 300mg Loading + 150mg Inhibitors | Treatment-related TEAE | 1 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) | Cohort 1: 300mg - 300mg Non-Inhibitor | All-causalities serious TEAE | 1 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) | Cohort 2: 300mg Loading + 150mg - 300mg Loading + 150mg Non-Inhibitor | All-causalities serious TEAE | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) | Cohort 3: 450mg - 300mg Loading + 150mg Non-Inhibitor | All-causalities serious TEAE | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) | Cohort 4: 300mg - 300mg Inhibitor | All-causalities serious TEAE | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) | Cohort 5: De Novo 300mg Loading + 150mg Inhibitors | All-causalities serious TEAE | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) | Cohort 1: 300mg - 300mg Non-Inhibitor | Treatment-related serious TEAE | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) | Cohort 2: 300mg Loading + 150mg - 300mg Loading + 150mg Non-Inhibitor | Treatment-related serious TEAE | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) | Cohort 3: 450mg - 300mg Loading + 150mg Non-Inhibitor | Treatment-related serious TEAE | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) | Cohort 4: 300mg - 300mg Inhibitor | Treatment-related serious TEAE | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) | Cohort 5: De Novo 300mg Loading + 150mg Inhibitors | Treatment-related serious TEAE | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03363321/results